Michael S. Weiss, Chairman and CEO at KERYX BIOPHARMACEUTICALS INC (KERX), sold 40,000 shares at $12.56 ($505K) on 2006-06-20, disclosed to the SEC on 2006-06-22.
Scheduled sale ($505k) by Chairman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.41 | 1,700 | $21K | 4.2% |
| 2 | $12.43 | 3,000 | $37K | 7.4% |
| 3 | $12.48 | 1,000 | $12K | 2.5% |
| 4 | $12.50 | 700 | $9K | 1.7% |
| 5 | $12.52 | 1,800 | $23K | 4.5% |
| 6 | $12.53 | 1,800 |
| $23K |
| 4.5% |
| 7 | $12.54 | 4,000 | $50K | 9.9% |
| 8 | $12.55 | 1,000 | $13K | 2.5% |
| 9 | $12.56 | 1,500 | $19K | 3.7% |
| 10 | $12.59 | 500 | $6K | 1.2% |
| 11 | $12.60 | 2,000 | $25K | 5.0% |
| 12 | $12.61 | 1,000 | $13K | 2.5% |
| 13 | $12.62 | 1,000 | $13K | 2.5% |
| 14 | $12.65 | 500 | $6K | 1.3% |
| 15 | $12.70 | 2,000 | $25K | 5.0% |
| 16 | $12.71 | 9,000 | $114K | 22.7% |
| 17 | $12.72 | 6,000 | $76K | 15.1% |
| 18 | $12.75 | 1,000 | $13K | 2.5% |
| 19 | $12.76 | 500 | $6K | 1.3% |
| Total | $12.61 avg | 40,000 | $505K | 100% |
| Filing → |
| FBIO | BUY | 2023-02-14 | $2.0M | — | Filing → |
| TGTX | SELL | 2022-01-07 | $2.6M | — | Filing → |
| TGTX | BUY | 2019-06-27 | $352K | — | Filing → |